McKee MD - Revive Therapeutics Chief Consultant
| RVVTF Stock | USD 0.01 0.0009 12.86% |
Insider
McKee MD is Chief Consultant of Revive Therapeutics
| Age | 72 |
| Phone | 888 901 0036 |
| Web | https://www.revivethera.com |
Revive Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4252) % which means that it has lost $0.4252 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8286) %, meaning that it generated substantial loss on money invested by shareholders. Revive Therapeutics' management efficiency ratios could be used to measure how well Revive Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Benjamin Kovler | Green Thumb Industries | 44 | |
| Stephan Bankosz | Vext Science | N/A | |
| Caitlin Johnston | Avicanna | N/A | |
| Dina Rollman | Green Thumb Industries | 50 | |
| Christine Hersey | Trulieve Cannabis Corp | N/A | |
| JD III | Trulieve Cannabis Corp | 54 | |
| Victoria Walker | Trulieve Cannabis Corp | 38 | |
| James Shorris | Curaleaf Holdings | 61 | |
| Camilo Lyon | Curaleaf Holdings | N/A | |
| Daniel Shaker | Green Thumb Industries | 52 | |
| Carlos Muete | Avicanna | N/A | |
| Swadheen Sehgal | Green Thumb Industries | N/A | |
| Peter JD | Curaleaf Holdings | 55 | |
| Bret Kravitz | Green Thumb Industries | 43 | |
| Steven White | Trulieve Cannabis Corp | 49 | |
| Jonathan Ross | Vext Science | N/A | |
| Rebecca Young | Trulieve Cannabis Corp | 42 | |
| Matthew Darin | Curaleaf Holdings | N/A | |
| Jason Nguyen | Vext Science | N/A | |
| Frantz Devedec | Avicanna | N/A | |
| Mba BEcon | Avicanna | N/A | |
Management Performance
| Return On Equity | -0.83 | |||
| Return On Asset | -0.43 |
Revive Therapeutics Leadership Team
Elected by the shareholders, the Revive Therapeutics' board of directors comprises two types of representatives: Revive Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revive. The board's role is to monitor Revive Therapeutics' management team and ensure that shareholders' interests are well served. Revive Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revive Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Frank, Chairman CEO | ||
| Derrick Welsh, COO Pharma | ||
| Onesmo Mpanju, Chief Consultant | ||
| ACIS BComm, Chief Officer | ||
| McKee MD, Chief Consultant |
Revive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Revive Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.83 | |||
| Return On Asset | -0.43 | |||
| Current Valuation | 32.12 M | |||
| Shares Outstanding | 353.56 M | |||
| Shares Owned By Insiders | 2.48 % | |||
| Shares Owned By Institutions | 2.42 % | |||
| Price To Earning | (4.10) X | |||
| Price To Book | 4.00 X | |||
| EBITDA | (17.74 M) | |||
| Net Income | (17.81 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Revive OTC Stock
Revive Therapeutics financial ratios help investors to determine whether Revive OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Revive with respect to the benefits of owning Revive Therapeutics security.